newsfilter
← Latest News
GlobeNewswire·

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other